ORIGINAL_ARTICLE
Serum Level of Melatonin and Severity of Coronary Artery Diseases
Background: Coronary Artery Disease (CAD) as a complex process will be the most common cause of death in the world by 2020. One of the relatively new factors associated with CAD is the plasma level of melatonin. This study aimed to determine the effect of plasma melatonin level on the occurrence and severity of CAD.Methods: This cross-sectional study was conducted from August to December 2018 in Kerman, Iran. Eighty-seven adolescents with suspected CAD were selected via the convenience sampling method. Severity of CAD was evaluated by a cardiologist for each patient using Gensini score. The anxiety, depression, and sleep disturbance of participants were examined by HADS and PSIQ questionnaires, respectively. The blood sample of patients was taken at 3:30 a.m. and it was immediately transferred to the laboratory for serum separation. A two-part model was used for data analysis using STATA software.Results:The mean age (±SD) of the participants was 54.0 (±10.83) years. Less than half of the patients experienced anxiety and depression symptoms during last month (33% and 42%, respectively). Results showed that more than half of the patients (n=51, 57.5%) were diagnosed as CAD patients. According to multivariate regression models, melatonin (AOR=0.96, 95% CI: 0.94, 0.98) and depression (β: 0.79, 95% CI: 0.06, 1.52) were determined as predictors for CAD occurrence and severity, respectively.Conclusion: Melatonin as a protective factor has an effect on the occurrence and severity of CAD, but the existence of some diseases like mental disorders can lead to a decrease in the plasma concentration of melatonin. By treating depression and improving melatonin synthesis and secretion cycle, the occurrence and severity of CAD may be decreased.
https://jkmu.kmu.ac.ir/article_91607_af1c2c91eee1d6dd4392c570dc6a8458.pdf
2021-03-01
116
126
10.22062/jkmu.2021.91607
Coronary Artery Diseases
depression
Melatonin
Hamidreza
Rashidinejad
h.rashidineja@gmail.com
1
Associate Professor, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Hamidreza
Nasri
dr_hnasri@yahoo.com
2
Associate Professor, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mohammad Ali
Pour Ahmadi
3
Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mansour
Moazenzadeh
mmoazenzadeh170@gmail.com
4
Associate Professor, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51(3):606.
1
Dominguez‐Rodriguez A, Abreu‐Gonzalez P, Sanchez‐Sanchez JJ, Kaski JC, Reiter RJ. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010; 49(1):14-22.
2
Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol 2009; 7(3):367-73.
3
Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010; 42(4):276-85.
4
Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44(1):16-25.
5
Yildiz M, Akdemir O. Assessment of the effects of physiological release of melatonin on arterial distensibility and blood pressure. Cardiol Young 2009; 19(2):198-203.
6
Girotti L, Lago M, Ianovsky O, Elizari MV, Dini A, Lloret SP, et al. Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 2003; 22(3):245-8.
7
Altun A, Yaprak M, Aktoz M, Vardar A, Betul U-A, Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002; 327(2):143-5.
8
Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995; 345(8962):1408.
9
Sakotnik A, Liebmann PM, Stoschitzky K, Lercher P, Schauenstein K, Klein W, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20(18):1314-7.
10
Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 2003; 89(1):103-7.
11
Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18(12 Pt 1):1614-8.
12
Garakyaraghi M, Siavash M, Alizadeh MK. Effects of melatonin on left ventricular ejection fraction and functional class of patients with heart failure: a randomized, double-blind, placebo-controlled trial. Journal of Research in Medical Sciences 2012; Special Issue (1):S13-16.
13
Sakotnik A, Liebmann PM, Stoschitzky K, Lercher P, Schauenstein K, Klein W, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20(18):1314-7.
14
Borchi E, Bargelli V, Stillitano F, Giordano C, Sebastiani M, Nassi PA, et al. Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2010; 1802(3):331-8.
15
Murphy PJ, Badia P, Myers BL, Boecker MR, Wright Jr KP. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav 1994; 55(6):1063-6.
16
Vijayasarathy K, Naidu KS, Sastry B. Melatonin metabolite 6-Sulfatoxymelatonin, Cu/Zn superoxide dismutase, oxidized LDL and malondialdehyde in unstable angina. Int J Cardiol 2010; 144(2):315-7.
17
Şehirli AÖ, Koyun D, Tetik Ş, Özsavcı D, Yiğiner Ö, Çetinel Ş, et al. Melatonin protects against ischemic heart failure in rats. J Pineal Res 2013; 55(2):138-48.
18
Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ, El‐Sokkary GH. Ischemia/reperfusion‐induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res 1998; 25(3):184-91.
19
Diez ER, Renna NF, Prado NJ, Lembo C, Ponce Zumino AZ, Vazquez‐Prieto M, et al. Melatonin, given at the time of reperfusion, prevents ventricular arrhythmias in isolated hearts from fructose‐fed rats and spontaneously hypertensive rats. J Pineal Res 2013; 55(2):166-73.
20
Guo X, Kuzumi E, Charman SC, Vuylsteke A. Perioperative melatonin secretion in patients undergoing coronary artery bypass grafting. Anesth Analg 2002; 94(5):1085-91.
21
Akpınar Z, Tokgöz S, Gökbel H, Okudan N, Uğuz F, Yılmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 2008; 161(2):253-7.
22
Amini P, Maroufizadeh S, Samani RO. Evaluating the factor structure, item analyses, and internal consistency of hospital anxiety and depression scale in Iranian infertile patients. Int J Reprod Biomed 2017; 15(5):287-96.
23
Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes 2003; 1:14.
24
Moghaddam JF, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath 2012; 16(1):79-82.
25
Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2019; 38(1):191-6.
26
Matsuda R, Kohno T, Kohsaka S, Fukuoka R, Maekawa Y, Sano M, et al. The prevalence of poor sleep quality and its association with depression and anxiety scores in patients admitted for cardiovascular disease: a cross-sectional designed study. Int J Cardiol 2017; 228:977-82.
27
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 2017; 34:10-22.
28
Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol 2018; 175(16):3190-9.
29
Jafarian Amiri SR, Zabihi A, Babaie Asl F, Sefidchian A, Bijanee A. Sleep quality and associated factors in hospitalized patients in Babol, Iran. Hormozgan Medical Journal 2011; 15(2):144-51. [In Persian].
30
Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, van den Berg JF, Verschuren WM. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN study. Sleep 2011; 34(11):1487-92.
31
Wiebe ST, Cassoff J, Gruber R. Sleep patterns and the risk for unipolar depression: a review. Nat Sci Sleep 2012; 4:63-71.
32
Srivastava P, Gupta R, Chari D, Rawat A, Goel D. Comparison of prevalence of obstructive sleep apnea, restless legs syndrome, and poor sleep quality in patients with coronary artery disease and depression. Somnologie 2016; 20(2):144-9.
33
Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, Cardinali DP, Brown GM. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Prog Neurobiol 2009; 88(4):264-71.
34
Palacios J, Khondoker M, Mann A, Tylee A, Hotopf M. Depression and anxiety symptom trajectories in coronary heart disease: associations with measures of disability and impact on 3-year health care costs. J Psychosom Res 2018; 104:1-8.
35
Hansen MV, Halladin NL, Rosenberg J, Gögenur I, Møller AM. Melatonin for pre‐and postoperative anxiety in adults. Cochrane Database of Systematic Reviews 2015; 4.
36
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PloS One 2013; 8(5):e63773.
37
Madsen MT, Isbrand A, Andersen UO, Andersen LJ, Taskiran M, Simonsen E, et al. The effect of MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome (MEDACIS): study protocol for a randomized controlled trial. Trials 2017; 18(1):81.
38
O’Neil A, Fisher AJ, Kibbey KJ, Jacka FN, Kotowicz MA, Williams LJ, et al. Depression is a risk factor for incident coronary heart disease in women: An 18-year longitudinal study. J Affect Disord 2016; 196:117-24.
39
Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, van Schaik DJ, Penninx BJ. Depression, anxiety and 6-year risk of cardiovascular disease. J Psychosom Res 2015; 78(2):123-9.
40
Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med 2002; 23(1):51-61.
41
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48(8):1527-37.
42
Schopfer DW, Regan M, Heidenreich PA, Whooley MA. Depressive symptoms, cardiac disease severity, and functional status in patients with coronary artery disease (from the Heart and Soul Study). Am J Cardiol 2016; 118(9):1287-92.
43
Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. American Journal of Hypertension 2015; 28(11):1295-302.
44
Bradley SM, Rumsfeld JS. Depression and cardiovascular disease. Trends in Cardiovascular Medicine 2015; 25(7):614-22.
45
ORIGINAL_ARTICLE
Evaluation of the Effect of Co-administration of IRAK Inhibitor and Pioglitazone on PPAR-γ, GLUT-4, TNF-α, and Leptin Genes Expression in Adipose Tissue of Insulin-resistant Mice
Background: The worldwide prevalence of diabetes is increasing. Diabetes is a complex disease that results from impaired secretion of insulin or insulin resistance. In adipose tissue, insulin increases glucose uptake by stimulating the transfer of glucose transporter type 4 (GLUT-4) to the plasma membrane. In this study, the effect of IRAK inhibitor (IRAKi) and pioglitazone on genes expression in adipose tissue of insulin resistant mice was evaluated. Methods: Mice were randomly divided into 6 groups (n= 8 each), five groups of which were fed a high-fat diet and one group received a normal diet for 12 weeks. The treatment with pioglitazone and IRAKi was performed for 2 weeks. At the end of the study, the animals were sacrificed and the adipose tissue and blood samples were collected. The expression of GLUT4, TNF-α, peroxisome proliferator-activated receptor gamma (PPARγ), and Lepin were determined by real-time PCR in the adipose tissue. The malondialdehyde (MDA) level and total antioxidant capacity (TAC) in serum were measured. Results were analyzed by SPSS 22. Results: The data showed that the combination of IRAKi and pioglitazone increased PPARγ expression, leptin and TAC levels in serum, and reduced TNF-α expression and MDA levels. The GLUT4 expression in adipose tissue was not significant between studied groups. Pioglitazone and IRAKi improved insulin function by inhibiting inflammation signaling. Conclusion: According to the results of this study, IRAKi may be an appropriate target for inhibiting inflammation and related disorders, including insulin resistance.
https://jkmu.kmu.ac.ir/article_91608_0abb8b6787b519f7b00fae8b13b5c7fa.pdf
2021-03-01
127
138
10.22062/jkmu.2021.91608
Diabetes Mellitus
insulin resistance
IRAK Inhibitor
GLU4
PPARγ
Pioglitazone
Saeedeh
Moinaldini
1
Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mostafa
Allahyari
mostafa.allah1993@gmail.com
2
Department of Biochemistry, Biophysics, Genetics and Nutrition, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
AUTHOR
Beydolah
Shahouzehi
bshahouzehi@gmail.com
3
Assistant Professor, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Hossein
Fallah
hf59ma@gmail.com
4
Assistant Professor, Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103(2):137-49.
1
Esteves JV, Enguita FJ, Machado UF. MicroRNAs-Mediated regulation of skeletal muscle GLUT4 expression and translocation in insulin resistance. J Diabetes Res 2017; 2017:7267910.
2
Craik C. 基因的改变NIH Public Access. Bone. 2008;23(1):1–7.
3
Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes Res Clin Pract 2014; 103(2):319-27.
4
De Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582(1):97-105.
5
Fang P, Yu M, Guo L, Bo P, Zhang Z, Shi M. Galanin and its receptors: a novel strategy for appetite control and obesity therapy. Peptides 2012; 36(2):331-9.
6
Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011; 18(2):139-43.
7
Xu P, Hong F, Wang J, Wang J, Zhao X, Wang S, et al. DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis. Biochim Biophys Acta Gen Subj 2017; 1861(11):2690-701.
8
Gillentine MA, Berry LN, Goin-Kochel RP, Ali MA, Ge J, Guffey D, et al. the cognitive and behavioral phenotypes of individuals with CHRNA7 duplications. J Autism Dev Disord 2017; 47(3):549-62.
9
Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, et al. Hepatic fatty acid transporter Cd36 Is a common target of LXR, PXR, and PPARγ in promoting steatosis. Gastroenterology 2008; 134(2):556-67.
10
Wang Z, Wesche H, Stevens T, Walker N, Yeh WC. IRAK-4 Inhibitors for Inflammation. Curr Top Med Chem 2009; 9(8):724-37.
11
Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol Biol 2012; 821:1-14.
12
Yadav H, Jain S, Yadav M, Sinha PR, Prasad GB, Marotta F. Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats. Dig Liver Dis 2009; 41(7):500-8.
13
Li Z, Younger K, Gartenhaus R, Joseph AM, Hu F, Baer MR, et al. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest 2015; 125(3):1081-97.
14
Vilela BS, Vasques AC, Cassani RS, Forti AC, Pareja JC, Tambascia MA, et al. The HOMA-adiponectin (HOMA-AD) Closely Mirrors the HOMA-IR Index in the screening of insulin resistance in the Brazilian metabolic syndrome study (BRAMS). PLoS One 2016; 11(8):e0158751.
15
Rogero MM, Calder PC. Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients 2018; 10(4):432.
16
Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23(5):205-15.
17
Kumari M, Wang X, Lantier L, Lyubetskaya A, Eguchi J, Kang S, et al. IRF3 promotes adipose inflammation and insulin resistance and represses browning. J Clin Invest 2016; 126(8):2839-54.
18
Kampmann U, Christensen B, Nielsen TS, Pedersen SB, Ørskov L, Lund S, et al. GLUT4 and UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PLoS One 2011; 6(11):e27854.
19
Al-Hilali HA, Abduljaleel AK. The role of TNF and Resistin Gene+ 299 (G/A) polymorphism in the development of insulin resistance in non-obese Type 2 Diabetes Mellitus Iraqi patients. Int J Curr Microbiol App Sci 2015; 4(10):475-86.
20
Xu H, Teoman Uysal K, David Becherer J, Arner P, Hotamisligil GS. Altered tumor necrosis factor-α (TNF-α) processing in adipocytes and increased expression of transmembrane TNF-α in obesity. Diabetes 2002; 51(6):1876-83.
21
Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen BK. Insulin stimulates interleukin-6 and tumor necrosis factor-α gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 2004; 286(2):E234-8.
22
Ahmad R, Shihab PK, Thomas R, Alghanim M, Hasan A, Sindhu S, et al. Increased expression of the interleukin-1 receptor-associated kinase (IRAK)-1 is associated with adipose tissue inflammatory state in obesity. Diabetol Metab Syndr 2015; 7:71.
23
Maitra U, Singh N, Gan L, Ringwood L, Li L. IRAK-1 contributes to lipopolysaccharide-induced reactive oxygen species generation in macrophages by inducing NOX-1 transcription and Rac1 activation and suppressing the expression of antioxidative enzymes. J Biol Chem 2009; 284(51):35403-11.
24
Rajaie A, Allahyari M, Nazari-Robati M, Fallah H. Inhibition of interleukin-1 receptor-associated kinases 1/4, increases gene expression and serum level of adiponectin in mouse model of insulin resistance. Int J Mol Cell Med 2018; 7(3):185-92.
25
Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, et al. Weight loss-associated induction of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004; 110(20):3259-69.
26
Jialal I, Adams-Huet B, Duong F, Smith G. Relationship between retinol-binding protein-4/adiponectin and leptin/adiponectin ratios with insulin resistance and inflammation. Metab Syndr Relat Disord 2014; 12(4):227-30.
27
Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C, et al. Role of leptin in the activation of immune cells. Mediators Inflamm 2010; 2010:568343.
28
Rahimipanah M, Hamedi M, Mirzapour M. Antioxidant activity and phenolic contents of Persian walnut ( Juglans regia L .) green husk extract. African Journal of Food Science and Technology 2010; 1(4):105-11.
29
Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, et al. Antioxidant status in patients with uncomplicated insulin‐dependent and non‐insulin‐dependent diabetes mellitus. Eur J Clin Invest 1997; 27(6):484-90.
30
Höhn A, König J, Grune T. Protein oxidation in aging and the removal of oxidized proteins. J Proteomics 2013; 92:132-59.
31
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9):1058-70.
32
Athreya K, Xavier MF. Antioxidants in the treatment of cancer. Nutr Cancer 2017; 69(8):1099-104.
33
ORIGINAL_ARTICLE
The Effect of CYP2C9 and VKORC1 Genetic Polymorphism on Warfarin Dose Requirements in a Sample of Iraqi Patients
Background: Warfarin is the most widely used oral anticoagulant for the prevention and treatment of thromboembolic disorders. Because of narrow therapeutic index and various genetic and non-genetic factors that influence the disposition of the drug, its dose undergoes a great variability. The aim of this study was to determine the allelic variants of CYP2C9 and VKORC1 genes in Iraqi patients, and to investigate the contribution of genetic on warfarin dose requirements.Methods: A cross sectional study was carried out on a sample of Iraqi patients from Baghdad city who were admitted to Ibn AL-Bitar Specialized Center for cardiac surgery. Blood samples of all patients were collected for both hematological and genetic analysis utilizing standard techniques.Results: The frequency of CYP2C9*3 allele was 9.4% whereas that of CYP2C9*2 allele was 13.7%. The frequency of (VKORC1-1639G) allele was 58.75% and the frequency of (VKORC1-1639A) allele was 41.25%. Patients’ daily warfarin doses were administered according to their genotype.Conclusion:It can be concluded that CYP2C9*3 and VKORC1 had significant effect on warfarin dose. New warfarin-dosing algorithm was developed based on CYP2C9*3 and VKORC1genotypes for predicting the required dose of warfarin.
https://jkmu.kmu.ac.ir/article_91609_2d0ae32bebc2fd37340d1839411915f3.pdf
2021-03-01
139
149
10.22062/jkmu.2021.91609
Warfarin dose
Warfarin pharmacogenetics
Warfarin pharmacogenomics
CYP2C9
VKORC1
Maha
Ali Saleh
1
Assistant lecturer Department of pharmacology Faculty of Pharmacy, Al-Rafidain University College Baghdad, Iraq
AUTHOR
Haitham Mahmood
Kadhim
2
Assistant Professor, Dept. of Pharmacology and Toxicology, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq
AUTHOR
Ahmed
Sahib
ahmed.alkhezaly@uokerbala.edu.iq
3
Professor, Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Kerbala, Iraq
LEAD_AUTHOR
Ahmed S
Abdulamir
4
Professor, Dept. of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
AUTHOR
Rafed
Altawil
5
Assistant Professor, Dept. of Internal Medicine (Cardiology), College of Medicine ,Al-Nahrain University, Baghdad, Iraq
AUTHOR
Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin–fourth edition. Br J Haematol 2011; 154(3):311-24.
1
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7):2329-33.
2
Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004; 4(1):40-8.
3
Dean L. Warfarin therapy and VKORC1 and CYP genotype. [cited 2019 Oct 12] Available from: https://www.ncbi.nlm.nih.gov/books/NBK84174/.
4
Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol 2010; 23(5):939-45.
5
Schwarz UI, Stein CM. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther 2006; 80(1):7-12.
6
Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5(4):262-70.
7
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84(3):326-31.
8
Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000; 91:865-68.
9
Hamajima N, Katsuda N, Matsuo K, Saito T, Ito LS, Ando M,et al. Smoking habit andinterleukin lB C-31T polymorphism. J Epidemiol 2001; 11(3):120-5.
10
Breslauer KJ, Frank R, Blöcker H, Marky LA. Predicting DNA duplex stability from the base sequence. Proc Natl AcadSci USA 1986; 86(11):3746-50.
11
D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2):645-9.
12
Jiang NX, Ge JW, Xian YQ, Huang SY, Li YS. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients. Biomed Rep 2016; 4(4):453-8.
13
Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet 2011; 56(4):290-5.
14
Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. J Assoc Physicians India 2012; 60:34-8.
15
Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120(2):181-6.
16
Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 2008; 396(1):76-9.
17
ORIGINAL_ARTICLE
Rating and Comparison of Well-known Cardiovascular Risk Factors in Kermanian Male Patients Using Fuzzy Linear Regression
Background:Cardiovascular diseases are still among the most important causes of death in different countries. There are several risk factors for the onset of this disease. The rating of these risk factors is very important for informing the community and planning for the future.Methods: Linear regression is one of the classic statistical methods that has many applications in medical sciences. When dealing with fuzzy data, it is not possible to use linear regression. The use of angiography to estimate the extent of congestion is associated with an estimate of more or less stenosis and the increase of atherosclerosis. Hence, this variable has been considered as a fuzzy variable. Fuzzy linear regression (FLR) was used to rank and compare the known risk factors for coronary artery occlusion.Results:After analyzing the data by least squares FLR, the most important risk factors included Family history, history of diabetes, age, history of hypercholesterolemia, history of cigarette smoking, Body Mass Index and history of hypertension respectively.Conclusion: When it is not possible to calculate the response variable or one of the independent variables examined in the model accurately, FLR, or to be more precise, regression in fuzzy environment can be a good alternative for conventional regression analysis.
https://jkmu.kmu.ac.ir/article_91610_6002c0c8d3d1701ff57d9a2e819db5f2.pdf
2021-03-01
150
156
10.22062/jkmu.2021.91610
Fuzzy linear regression
Gensini score
Cardiovascular risk factors
Milad
Ahmadi Gohari
mi.ahmadi@yahoo.com
1
Modeling in Health Research Center, Institute for Futures Studies in Health & Department of Biostatistics and Epidemiology, Faculty of Health, Kerman university of Medical Sciences, Kerman, Iran
AUTHOR
Mansour
Moazenzadeh
msv_swt@yahoo.com
2
Assistant Professor, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Alireza
Rashidinejad
rashidinejadalireza@gmail.com
3
Department of Cardiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
AUTHOR
Abbas
Bahrampour
abahrampour@yahoo.com
4
Professor of Biostatistics, Modeling in Health Research Center, Institute for Futures Studies in Health & Department of Biostatistics and Epidemiology, Faculty of Health, Kerman university of Medical Sciences, Kerman, Iran 5-Adjunct Professor of Griffith University, Brisbane, QLD, Australia. (
LEAD_AUTHOR
WHO. Cardiovascular diseases. [cited 2021 Feb 12] Available from: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1.
1
WHO. Cardiovascular diseases (CVDs). [cited 2021 Feb 12] Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2
Saadat S, Yousefifard M, Asady H, Moghadas Jafari A, Fayaz M, Hosseini M. The most important causes of death in Iranian population; a retrospective cohort study. Emerg (Tehran) 2015; 3(1):16-21.
3
Sadeghi M, Haghdoost AA, Bahrampour A, Dehghani M. Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: the impact of demographic changes. Iranian Journal of Public Health 2017; 46(4):506-16.
4
Sarrafzadegan N, Mohammmadifard N. Cardiovascular disease in Iran in the last 40 years: prevalence, mortality, morbidity, challenges and strategies for cardiovascular prevention. Arch Iran Med 2019; 22(4):204-10.
5
Bots SH, Peters SA, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Glob Health 2017; 2(2):e000298.
6
Carter HE, Schofield D, Shrestha R. Productivity costs of cardiovascular disease mortality across disease types and socioeconomic groups. Open Heart 2019; 6(1):e000939.
7
Zdrenghea D, Guşetu G, Zdrenghea M, Cismaru G, Caloian B, Vaidean G, et al. CV RISK–A new relative cardiovascular risk score. Medical Hypotheses 2019; 132:109362.
8
Zhang Y, Cong H, Man C, Su Y, Sun H, Yang H, et al. Risk factors for cardiovascular disease from a population-based screening study in Tianjin, China: a cohort study of 36,215 residents. Ann Transl Med 2020; 8(7):444.
9
Psaltopoulou T, Hatzis G, Papageorgiou N, Androulakis E, Briasoulis A, Tousoulis D. Socioeconomic status and risk factors for cardiovascular disease: impact of dietary mediators. Hellenic J Cardiol 2017; 58(1):32-42.
10
Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for gensini score calculation. Atherosclerosis 2019; 287:181-3.
11
Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST, et al. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am Heart J 2012; 164(4):547-52.
12
Tanaka H. Fuzzy data analysis by possibilistic linear models. Fuzzy Sets and Systems 1987; 24(3):363-75.
13
Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165(6):710-8.
14
Scheuner MT, Whitworth WC, McGruder H, Yoon PW, Khoury MJ. Expanding the definition of a positive family history for early-onset coronary heart disease. Genet Med 2006; 8(8):491-501.
15
D'Urso P, Gastaldi T. A least-squares approach to fuzzy linear regression analysis. Computational Statistics & Data Analysis 2000; 34(4):427-40.
16
Shapiro AF. Fuzzy regression models. Article of Penn State University 2005; 102(2):373-83.
17
Ross TJ. Fuzzy Logic with Engineering Applications. 3th ed. UK: Wiley; 2010. p. 89-111.
18
Sadeghpour Gildeh B, Gine D. A goodness of fit index to reliability analysis in fuzzy model. [cited 2020 Oct 11] Available from: http://www.wseas.us/e-library/conferences/switzerland2002/papers/391.pdf.
19
Chacko M, Sarma PS, Harikrishnan S, Zachariah G, Jeemon P. Family history of cardiovascular disease and risk of premature coronary heart disease: a matched case-control study. Wellcome Open Res 2020; 5:70.
20
Hudspeth B. The burden of cardiovascular disease in patients with diabetes. Am J Manag Care 2018; 24(13 Suppl):S268-S72.
21
Gong FF, Coller JM, McGrady M, Boffa U, Shiel L, Liew D, et al. Age‐related longitudinal change in cardiac structure and function in adults at increased cardiovascular risk. ESC Heart Fail 2020; 7(3):1344-61
22
Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, et al. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013; 61(14):1510-7.
23
Khoramdad M, Vahedian‐azimi A, Karimi L, Rahimi‐Bashar F, Amini H, Sahebkar AJIl. Association between passive smoking and cardiovascular disease: a systematic review and meta‐analysis. IUBMB Life 2020; 72(4):677-86.
24
Formentini FS, Nagano FE, Neto FD, Adam EL, Fortes FS, da Silva LF. Coronary artery disease and body mass index: What is the relationship? Clinical Nutrition ESPEN 2019; 34:87-93.
25
Jazayeri MA, Waheed S, Shah Z, Parashara D, Gupta K. Impact of body mass index on the association of ankle-brachial index with all-cause and cardiovascular mortality: results from the national health and nutrition examination survey. Mayo Clin Proc Innov Qual Outcomes 2019; 3(4):409-17.
26
Tackling G, Borhade MB. Hypertensive heart disease. [cited 2021 Feb 28] Available from: https://www.ncbi.nlm.nih.gov/books/NBK539800/.
27
Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1 8 million participants. Lancet 2014; 383(9921):970-83.
28
Tzoulaki I, Elliott P, Kontis V, Ezzati MJC. Worldwide exposures to cardiovascular risk factors and associated health effects: current knowledge and data gaps. Circulation 2016; 133(23):2314-33.
29
ORIGINAL_ARTICLE
Association between Depression and Food Insecurity in Patients with Diabetes: a cross-sectional study
Background:We sought to determine whether there is a linear trend between different levels of depression and different food security/insecurity situations in patients with diabetes mellitus. Methods:Two hundred women with diabetes mellitus referred to the diabetic clinic of Shaheed Bahonar, Kerman/ Iran and aged 35-75 years were enrolled randomly in a descriptive-analytic cross-sectional study. The patients completed Beck Depression Inventory-II (BDI-II) and Food Security Questionnaire (HFIAS). Pearson's Chi-Square test was carried out to assess whether depressive disorders and household food security/insecurity were related. Results:There was a significant association between the four-level variable of depressive disorders and the four-level variable of food security/insecurity (X2 ≥ 29.545, p=0.001). There was a significant association between the two-level variable of depressive disorders and the four-level variable of food security/insecurity (X2 ≥ 9.878, p=0.020). There was also a significant association between the two-level variable of depressive disorders (normal and depressive diabetic patients) and the two-level variable of food security/insecurity (food secure and insecure diabetic patients) (X2 ≥ 6.073, p=0.014). About half (47%) of the patients with mild to extreme depression had mild to severe food insecurity. However, two-thirds of the patients in the normal situation were food secure (p=0.014). Conclusion:We found enough evidence to suggest a significant association between household food security/insecurity and depressive disorders. The value of the linear by linear association test for trend was shown to be significant and indicated that household food insecurity trends to rise with values of depressive disorders. Therefore, the more severe the depression, the greater the food insecurity.
https://jkmu.kmu.ac.ir/article_91611_1e96b57bda26b76c0f99bd098a99a15a.pdf
2021-03-01
157
166
10.22062/jkmu.2021.91611
depression
Diabetes
Food security
Insecurity
Mohammad Reza
Mahmoodi
mahmoodimr@yahoo.com
1
Associate professor of Nutrition & Medical Education Fellowship, Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Adeleh
Khodabakhshi
khodabakhshiadeleh@yahoo.com
2
Assistant professor of Nutrition, Department of Nutrition, Faculty of Public Health, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Anderson SA. Core indicators of nutritional state for difficult-to-sample populations. The Journal of nutrition (USA). 1990.
1
Stuff JE, Casey PH, Szeto KL, Gossett JM, Robbins JM, Simpson PM, et al. Household food insecurity is associated with adult health status. The Journal of nutrition. 2004;134(9):2330-5.
2
Hamelin A-M, Habicht J-P, Beaudry M. Food insecurity: consequences for the household and broader social implications. The Journal of nutrition. 1999;129(2):525S-8S.
3
Najibi N, Firoozi R, Shahrezaee S, Eshraghian M, Daneshi-Maskooni M, Dorosty-Motlagh A. Food insecurity is an important risk factor for type 2 diabetes: a case-control study of new referrals to the University clinics, Shiraz, Southern Iran. BMC public health. 2019;19(1):885.
4
Ramesh T, Dorosty A, Abdollahi M. Prevalence of food insecurity in household of Shiraz and association with some of socioeconomic and population factors. Iranian Journal of Nutrition Sciences and Food Technology. 2010;4(4):53-64.
5
Ostadrahimi A, Mahboub S, Totonchi H, Dastgiri S, Dadgar L. Prevalence rate and range of food insecurity of two dimension visible and nonvisible hungry in asadabad, tabriz. Research Journal of Lorestan University of Medical Sciences. 2007;8(1):61-6.
6
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes care. 1998;21(9):1414-31.
7
Haghdoost A, Rezazadeh Kermani M, Sadghirad B, Baradaran H. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. EMHJ-Eastern Mediterranean Health Journal, 15 (3), 591-599, 2009. 2009.
8
Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes care. 2008;31(1):96-8.
9
Dorosty AR. Food insecurity and chronic diseases: the editorial. Nutrition and Food Sciences Research. 2016;3(3):1-2.
10
Seligman HK, Jacobs EA, Lopez A, Tschann J, Fernandez A. Food insecurity and glycemic control among low-income patients with type 2 diabetes. Diabetes care. 2012;35(2):233-8.
11
Seligman HK, Bindman AB, Vittinghoff E, Kanaya AM, Kushel MB. Food insecurity is associated with diabetes mellitus: results from the National Health Examination and Nutrition Examination Survey (NHANES) 1999–2002. Journal of general internal medicine. 2007;22(7):1018-23.
12
Montgomery J, Lu J, Ratliff S, Mezuk B. Food insecurity and depression among adults with diabetes: results from the National Health and Nutrition Examination Survey (NHANES). The Diabetes Educator. 2017;43(3):260-71.
13
Noorbala A, Azizi F, Hatami H, Janghorbani M. Epidemiology and control of prevalent disease in Iran. Tehran: Khosravi Publication. 2004:265-79.
14
Kolovos S, Zavala GA, Leijen AS, Melgar-Quiñonez H, van Tulder M. Household food insecurity is associated with depressive symptoms: results from a Mexican population-based survey. Food Security. 2020;12(2):407-16.
15
Farzaneh H, Pourghassem Gargari B, Asghari Jafarabadi M, Lalezadeh Z, Arzhang P, Farzaneh A. Depression and Its Association with Food Insecurity in Household Women Living in Northwest of Iran. Nutrition and Food Sciences Research. 2019;6(2):5-12.
16
Lee SJ, Lee KW, Cho MS. Association of Food Insecurity with Nutrient Intake and Depression among Korean and US Adults: Data from the 2014 Korea and the 2013–2014 US National Health and Nutrition Examination Surveys. International Journal of Environmental Research and Public Health. 2021;18(2):506.
17
Salarkia N, Abdollahi M, Amini M, Neyestani TR. An adapted Household Food Insecurity Access Scale is a valid tool as a proxy measure of food access for use in urban Iran. Food Security. 2014;6(2):275-82.
18
Beck AT. Cognitive therapy of depression: Guilford press; 1979.
19
Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian‐language version of the Beck Depression Inventory‐Second edition: BDI‐II‐PERSIAN. Depression and anxiety. 2005;21(4):185-92.
20
Mahmoodi MR, Najafipour H, Mohsenpour MA, Amiri M. The relationship between food insecurity with cardiovascular risk markers and metabolic syndrome components in patients with diabetes: A population-based study from Kerman coronary artery disease risk study. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2017;22.
21
Siahipour S, Khodabakhshi A, Mehrad-Majd H, Noroozi M, Moghadam SAHZ. Study of food security and its related factors in Iranian families referred to health centers in Qazvin. Progress in Nutrition. 2019;21(1-S):321-8.
22
Sotoudeh M, Safarian M, Dorosty A, Dashipour A, Khodabakhshi A, Montazerifar F. The Association of Food Insecurity and Dietary Patterns with Simultaneous Obesity and Stunting in Primary School Pupils of Zahedan City (Iran). Iranian Journal of Nutrition Sciences & Food Technology. 2016;10(4):53-62.
23
Sotoudeh M, Motlagh A, Dashipoor A, Gholampour Z, Khodabakhshi A. Evaluation of dietary quality of stunting children with stimulant overweight using healthy eating index. International Journal of Pharmacy and Technology. 2016;8(2):12304-14.
24
Payab M, Motlagh A-rD, Eshraghian M, Rostami R, Siassi F. The association of family food security and depression in mothers having primary school children in Ray-Iran. Journal of Diabetes & Metabolic Disorders. 2014;13(1):65.
25
Zehni Moghadam SA, Javadi M, Mohammadpour A, Khodabakhshi A. Assessment of Food Security Status with lipid profile and body mass index in patients with type 2 diabetes. J Biol Today’s World. 2016;5(9):169-72.
26
Kaviani H, Mousavi A. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran University Medical Journal TUMS Publications. 2008;66(2):136-40.
27
Mazloomy S, Mirzaei A, Mohammadi S. Study of depression prevalence in the patients with type II diabetes referring to Yazd diabetes research centers in 2008. 2008.
28
De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosomatic medicine. 2001;63(4):619-30.
29
Hasan SS, Mamun AA, Clavarino AM, Kairuz T. Incidence and risk of depression associated with diabetes in adults: evidence from longitudinal studies. Community mental health journal. 2015;51(2):204-10.
30
Lyoo IK, Yoon S, Jacobson AM, Hwang J, Musen G, Kim JE, et al. Prefrontal cortical deficits in type 1 diabetes mellitus: brain correlates of comorbid depression. Archives of general psychiatry. 2012;69(12):1267-76.
31
Ho N, Sommers MS, Lucki I. Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neuroscience & Biobehavioral Reviews. 2013;37(8):1346-62.
32
Whitaker RC, Phillips SM, Orzol SM. Food insecurity and the risks of depression and anxiety in mothers and behavior problems in their preschool-aged children. Pediatrics. 2006;118(3):e859-e68.
33
34. Siefert K, Heflin CM, Corcoran ME, Williams DR. Food insufficiency and the physical and mental health of low-income women. Women & health. 2001;32(1-2):159-77.
34
Seligman HK, Laraia BA, Kushel MB. Food insecurity is associated with chronic disease among low-income NHANES participants. The Journal of nutrition. 2009;140(2):304-10.
35
Silverman J, Krieger J, Kiefer M, Hebert P, Robinson J, Nelson K. The relationship between food insecurity and depression, diabetes distress and medication adherence among low-income patients with poorly-controlled diabetes. Journal of general internal medicine. 2015;30(10):1476-80.
36
Drewnowski A, Darmon N. Food choices and diet costs: an economic analysis. The Journal of nutrition. 2005;135(4):900-4.
37
Sánchez-Villegas A, Toledo E, De Irala J, Ruiz-Canela M, Pla-Vidal J, Martínez-González MA. Fast-food and commercial baked goods consumption and the risk of depression. Public health nutrition. 2012;15(3):424-32.
38
Sánchez-Villegas A, Verberne L, De Irala J, Ruiz-Canela M, Toledo E, Serra-Majem L, et al. Dietary fat intake and the risk of depression: the SUN Project. PloS one. 2011;6(1):e16268.
39
Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Archives of internal medicine. 2000;160(21):3278-85.
40
ORIGINAL_ARTICLE
Follow-up and Outcome of Olfactory and Gustatory Dysfunctionsin Patients with COVID-19
Background: Olfactory and gustatory dysfunctions can be considered as important symptoms to screen for the mild cases of the COVID-19 disease. However, there are limited studies on the specificity of olfactory and gustatory changes in patients with COVID-19, and it is unclear to what extent the changes may be unique to the disease. This study aimed to evaluate the duration and outcome of olfactory and gustatory disorders in patients with COVID-19.Methods: The study population was patients with COVID-19 at Afzalipour Hospital whose disease was confirmed by nasopharyngeal polymerase chain reaction (PCR) test. 20 patients with olfactory and gustatory dysfunctions were studied. Data were collected using two forms, which were completed at the time of diagnosis and two weeks after the onset of the disease.Results: In 20% of the patients, olfactory and gustatory dysfunctions were among the early symptoms. In 85% of the cases, these dysfunctions were permanent during the disease. 30% of the cases had a chronic underlying disease such as sinusitis, nasal polyps, and allergy. In follow-up, 13 patients (60%) reported that their olfactory dysfunctions had completely improved.Conclusion: The patients whose only symptom is the sudden olfactory or gustatory dysfunction or the dysfunctions are among their early symptoms, should be screened for COVID-19. Most of the patients will recover over the time.
https://jkmu.kmu.ac.ir/article_91612_3f346819417b5edf17dc7b5f94c7df39.pdf
2021-03-01
167
172
10.22062/jkmu.2021.91612
Olfactory Dysfunction Gustatory Dysfunction COVID
19
Ali
Hosseininasab
ali4221@yahoo.com
1
Associate Professor, Infectious and Tropical Research Center, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mehrdad
Farokhnia
mehrdad_farrokhnia@yahoo.com
2
Assistant Professor, Department of Internal Medicine, Infectious and Tropical Research Center, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Ali-Asghar
Arabi Mianroodi
3
Assistant Professor, Department of Head and Neck Surgery, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Elham
Iranmanesh
e.iranmanesh@gmail.com
4
MD, Department of Pediatrics. Resident of Pediatrics, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Sobhan
Mohammadi
sobhan.mohammadi.hd@gmail.com
5
Medical Student, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Adel
Soltani
a.bast@ymail.com
6
Medical Student, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mehran
Ilaghi
mehranila@gmail.com
7
Medical Student, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Saja
Shahdforush
8
Medical Student, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Alireza
Hashemi
mpmahyabadi77@gmail.com
9
Medical Student, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Samimi Ardestani SH, Mohammadi Ardehali M, Rabbani Anari M, Rahmaty B, Erfanian R, Akbari M, et al. The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD). Acta Otolaryngol 2020; 141(2):171-80.
1
van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol 2015; 235(2):277-87.
2
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277(8):2251-61.
3
Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I. Olfactory dysfunction in the COVID-19 outbreak. J Investig Allergol Clin Immunol 2020; 30(5):30.
4
Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics. Otolaryngol Head Neck Surg 2020; 163(1):114-20.
5
Otte MS, Klussmann JP, Luers JC. Persisting olfactory dysfunction in patients after recovering from COVID-19. J Infect 2020; 81(3):e58.
6
D'Ascanio L, Pandolfini M, Cingolani C, Latini G, Gradoni P, Capalbo M, et al. Olfactory Dysfunction in COVID-19 Patients: Prevalence and Prognosis for Recovering Sense of Smell. Otolaryngol Head Neck Surg 2020; 164(1):82-6.
7
Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Plzak J, Hans S, et al. Psychophysical olfactory tests and detection of COVID-19 in patients with sudden onset olfactory dysfunction: a prospective study. Ear Nose Throat J 2020; 99(9):579-83.
8
Kosugi EM, Lavinsky J, Romano FR, Fornazieri MA, Luz-Matsumoto GR, Lessa MM, et al. Incomplete and late recovery of sudden olfactory dysfunction in COVID-19. Braz J Otorhinolaryngol 2020; 86(4):490-6.
9
ORIGINAL_ARTICLE
The Association of Psoriatic Arthritis with Carotid Intima-Media Thickness
Background: Previous studies have showed that psoriatic arthritis increases the risk of cardiovascular disease and atherosclerosis. On the other hand, an increased carotid intima-media thickness can be associated with atherosclerosis. The present study aimed to evaluate the association between psoriatic arthritis and carotid intima-media thickness.Methods: In this case-control study performed during 2018, 22 patients with psoriatic arthritis and 22 healthy controls matched for age and sex were participated. In all subjects, the carotid intima-media thickness was measured by ultrasonography. Systemic inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were assessed in psoriatic arthritis patients.Results: The mean carotid intima-media thickness was 56±0.10 mm in the psoriatic arthritis patients and 54±0.07 mm in the control group with no significant difference (p=0.358). According to the regression analysis, carotid intima-media thickness had no positive correlation with age, sex and body mass index. The carotid intima-media thickness increased in psoriatic arthritis patients with increasing the duration of arthritis, disease activity (DAS-28), CRP, and ESR, but the correlations were not statistically significant.Conclusion: The study findings do not support the previous reports that claimed a potential correlation between mean carotid intima-media thickness and psoriatic arthritis.
https://jkmu.kmu.ac.ir/article_91613_8773fa124cdb0e74b50bb3046b3e197a.pdf
2021-03-01
173
178
10.22062/jkmu.2021.91613
Arthritis Psoriatic Carotid Intima
Media Thickness
Hamidreza
Talari
talari21@yahoo.com
1
Associate Professor, Department of Radiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Mojtaba
Sehat
sehat1@gmail.com
2
Associate Professor, Department of Community Medicine, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Mohammad
Shayestehpour
m.shayesteh@gmail.com
3
Assistant Professor, Autoimmune Diseases Research Center & Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Khatereh
Minaee
minaee55@yahoo.com
4
Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Batool
Zamani
batol_zamani2007@yahoo.com
5
Associate Professor, Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
LEAD_AUTHOR
Pelechas E, Kaltsonoudis E, Voulgari P, Drosos A. Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Switzerland: Springer; 2019. p. 93-119.
1
Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis 2012; 2012:176298.
2
Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008; 59(9):1322-31.
3
Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, et al. Autoimmun Rev 2011; 10(12):773-8.
4
Carbone F, Bonaventura A, Liberale L, Paolino S, Torre F, Dallegri F, et al. Atherosclerosis in rheumatoid arthritis: promoters and opponents. Clin Rev Allergy Immunol 2018; 58(1):1-14.
5
Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids 2015; 2015:971453.
6
Bańska-Kisiel K, Haberka M, Bergler-Czop B, Brzezińska-Wcisło L, Okopień B, Gąsior Z. Carotid intima-media thickness in patients with mild or moderate psoriasis. Postepy Dermatol Alergol 2016; 33(4):286-9.
7
Weber LA, Cheezum MK, Reese JM, Lane AB, Haley RD, Lutz MW, et al. Cardiovascular imaging for the primary prevention of atherosclerotic cardiovascular disease events. Curr Cardiovasc Imaging Rep 2015; 8(9):36.
8
Darabian S, Hormuz M, Latif MA, Pahlevan S, Budoff MJ. The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. Curr Atheroscler Rep 2013; 15(3):306.
9
Yiu KH, Yeung CK, Zhao CT, Chan JC, Siu CW, Tam S, et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med 2013; 273(3):273-82.
10
Balci DD, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23(1):1-6.
11
Yilmazer B, Sahin T, Unlu BO, Kir HM, Cefle A. Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 2015; 35(8):1385-92.
12
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54(8):2665-73.
13
Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35(5):877-82.
14
Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31(3):705-12.
15
Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36(4):203-9.
16
Mazlan SA, bin Mohamed Said MS, Hussein H, binti Shamsuddin K, Shah SA, Basri H. A study of intima media thickness and their cardiovascular risk factors in patients with psoriatic arthritis. Acta Medica (Hradec Kralove) 2009; 52(3):107-16.
17
Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, et al. [Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]. Reumatismo 2009; 61(4):298-305. [In Italian].
18
ORIGINAL_ARTICLE
Isoenzyme Characterization of Trichomonas vaginalis Isolated from HIV Patients in Fars and Kerman, Southeast Iran
Background: Trichomonas vaginalis is an anaerobic flagellated protozoan which is responsible for human urogenital infections. Several zymodemes of T. vaginalis have been reported from various parts of the worlds on the basis of isoenzyme patterns. This study was conducted to characterize the isolated organisms of T. vaginalis from HIV patients using isoenzyme electrophoresis in Fars and Kerman provinces, southeast Iran.Methods: Eighteen mass cultivated isolates of T. vaginalis in the modified TYI-S-33 medium were analyzed using isoenzyme electrophoresis. Polyacrylamide gel electrophoresis (PAGE) of five different enzyme systems were used to characterize T. vaginalis isolates: (i) Glucose-6-phosphate dehydrogenase (G6PD), (ii) Glucose phosphate isomerase (GPI), (iii) Malate dehydrogenase (MDH), (iv) Malic enzyme (ME), and (v) Phosphoglucomutase (PGM). Results: MDH, GPI, PGM, and ME enzyme systems showed a homogeneity and detected an identical enzyme pattern in all isolates. Meanwhile, G6PD revealed two different enzyme patterns. The isoenzyme electrophoretic profiles divided 18 T. vaginalis isolates into two zymodemes. Zymodeme 1 contained Shiraz isolates and zymodeme 2 contained Kerman isolates.Conclusion:The polymorphism of Iranian human isolates of T. vaginalis could be assessed by biochemical study using appropriate enzyme systems. Isoenzyme analysis is a promising method for the characterization of T. vaginalis. New molecular studies with increased number of enzyme loci and genetic markers are suggested to classify more zymodemes of Trichomonas in Iran.
https://jkmu.kmu.ac.ir/article_91614_3510119b9062dcf1c8e2c1057ba6800c.pdf
2021-03-01
179
186
10.22062/jkmu.2021.91614
Trichomonas vaginalis
HIV
Isoenzyme Electrophoresis
Zymodeme
Arghavan
Vafafar
avafafar@yahoo.com
1
Instructor, Department of Parasitology and Mycology‚ School of Medicine‚ Shiraz University of Medical Sciences, Shiraz‚ Iran
AUTHOR
Naser
Ziaali
naserzia@yahoo.com
2
Associate Professor, Research Center for Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Razieh
Tavakoli
rahavard44@yahoo.com
3
Assistant Professor, Department of Parasitology and Mycology‚ School of Medicine‚ Kerman University of Medical Sciences, Kerman‚ Iran
AUTHOR
Mohammad
Rayani
rayani@bpums.ac.ir
4
Assistant Professor, The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
AUTHOR
Gholamreza
Hatam
hatamghr@sums.ac.ir
5
Professor, Basic Sciences in Infectious Diseases Research Center‚ Shiraz University of Medical Sciences, Shiraz‚ Iran
LEAD_AUTHOR
Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 2008; 21(1):56-64.
1
Kashan ZF, Arbabi M, Delavari M, Hooshyar H, Taghizadeh M, Joneydy Z. Effect of Verbascum thapsus ethanol extract on induction of apoptosis in Trichomonas vaginalis in vitro. Infect Disord Drug Targets 2015; 15(2):125-30.
2
Arbabi M, Delavari M, Fakhrieh-Kashan Z, Hooshyar H. Review of Trichomonas vaginalis in Iran, based on epidemiological situation. J Reprod Infertil 2018; 19(2):82-8.
3
Hezarjaribi HZ, Fakhar M, Shokri A, Teshnizi SH, Sadough A, Taghavi M. Trichomonas vaginalis infection among Iranian general population of women: a systematic review and meta-analysis. Parasitol Res 2015; 114(4):1291-300.
4
Meade JC, Carlton JM. Genetic diversity in Trichomonas vaginalis. Sex Transm Infect 2013; 89(6):444-8.
5
Secor WE, Meites E, Starr MC, Workowski KA. Neglected parasitic infections in the United States: trichomoniasis. Am J Trop Med Hyg 2014; 90(5):800-4.
6
Thompson RC, Meloni BP. Molecular variation in Giardia. Acta Trop 1993; 53(3-4):167-84.
7
Hatam GR, Hosseini SM, Ardehali S. Isoenzyme studies in characterization of Leishmania isolated in Iran. Iran J Med Sci 1999; 24(1-Jan):8-13.
8
Meloni B, Lymbery AJ, Thompson RC. Genetic characterization of isolates of Giardia duodenalis by enzyme electrophoresis: implications for reproductive biology, population structure, taxonomy, and epidemiology. J Parasitol 1995; 81(3):368-83.
9
Miles M, Lainson R, Shaw J, Povoa M, De Souza A. Leishmaniasis in Brazil: XV. Biochemical distinction of Leishmania mexicana amazonensis, L. braziliensis braziliensis and L. braziliensis guyanensis-aetiological agents of cutaneous leishmaniasis in the Amazon Basin of Brazil. Trans R Soc Trop Med Hyg 1981; 75(4):524-9.
10
Ebert F. Further isoenzymatic studies on Trypanosoma cruzi stocks from Brazil, Colombia and Chile. Trop Med Parasit 1985; 36(2):85-7.
11
Darde ML, Bouteille B, Pestre-Alexandre M. Isoenzymic characterization of seven strains of Toxoplasma gondii by isoelectrofocusing in polyacrylamide gels. Am J Trop Med Hyg 1988; 39(6):551-8.
12
Sargeaunt PG, Baveja UK, Nanda R, Anand BS. Influence of geographical factors in the distribution of pathogenic zymodemes of Entamoeba histolytica: identification of zymodeme XIV in India. Trans R Soc Trop Med Hyg 1984; 78(1):96-101.
13
Homan WL, Van Enckevort FV, Limper L, Van Eys GJ, Schoone GJ, Kasprzak W, et al. Comparison of Giardia isolates from different laboratories by isoenzyme analysis and recombinant DNA probes. Parasitol Res 1992; 78(4):316-23.
14
Rayani M, Unyah NZ, Vafafar A, Hatam GR. Isoenzyme profiles and phylogenetic analysis of Giardia duodenalis isolates from Iranian patients. Environ Sci Pollut Res 2020; 27(32):40652-63.
15
Keister DB. Axenic culture of Giardia lamblia in TYI-S-33 medium supplemented with bile. Trans R Soc Trop Med Hyg 1983; 77(4):487-8.
16
Clark CG, Diamond LS. Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev 2002; 15(3):329-41.
17
Hatam GR, Bahrami S, Razavi SM, Oryan A. Isoenzyme and ultrastructural characterization of Leishmania tropica axenic amastigotes and promastigotes. Parasitol Res 2013; 112(2):643-8.
18
Hatam GR, Riyad M, Bichichi M, Hejazi SH, Guessous-Idrissi N, Ardehali S. Isoenzyme characterization of iranian leishmania isolates from cutaneous leishmaniasis. Iran J Sci Technol Trans A Sci 2005; 29(1):65-70.
19
Evans D. Handbook on Isolation, Characterization and Cryopreservation of Leishmania. Geneva: WHO; 1989.
20
Chýle M, Štěpán J, Chýle P, Patočka F. Some enzyme and isoenzyme activities in Trichomonas vaginalis. Folia Microbiol 1971; 16(2):142-3.
21
Soliman MA, Ackers JP, Catterall RD. Isoenzyme characterisation of Trichomonas vaginalis. Br J Vener Dis 1982; 58(4):250-6.
22
Coombs GH, North MJ. An analysis of the proteinases of Trichomonas vaginalis by polyacrylamide gel electrophoresis. Parasitology 1983; 86(Pt 1):1-6.
23
Gradus MS, Matthews HM. Electrophoretic analysis of soluble proteins and esterase, superoxide dismutase and acid phosphatase isoenzymes of members of the protozoan family trichomonadidae. Comp Biochem Physiol B 1985; 81(1):229-33.
24
Nadler SA, Honigberg BM. Genetic differentiation and biochemical polymorphism among trichomonads. J Parasitol 1988; 74(5):797-804.
25
Proctor EM, Naaykens W, Wong Q, Bowie WR. Isoenzyme patterns of isolates of Trichomonas vaginalis from Vancouver. Sex Transm Dis 1988; 15(4):181-5.
26
Vohra H, Sharma P, Sofi BA, Gupta I, Ganguly NK, Mahajan RC, et al. Correlation of zymodeme patterns, virulence & drug sensitivity of Trichomonas vaginalis isolates from women. Indian J Med Res 1991; 93:37-9.
27
Azab ME, Salem SA, Abd el Ghaffar FM, el Sherif EA, Habib KS, Habib FS. Characterization of Egyptian isolates of Trichomonas vaginalis: I. Serotyping. J Egypt Soc Parasitol 1992; 22(3):775-82.
28
Yuan LJ, Gao XZ. [Isoenzyme analysis on different isolates of Trichomonas vaginalis]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003; 21(2):102-5. [In Chinese].
29
ORIGINAL_ARTICLE
Is Computed Tomography Necessary for the Diagnosis of Coronavirus Disease (COVID–19) in all Suspected Patients? A case series
Coronavirus disease 2019 (COVID–19), reported pandemic in March 2020, is the current health problem with no definite prevention or treatment. As a newly emerging disease, new cases are reported each day to add to the physician’s knowledge about the best clinical approach. One of the controversies in this regard is the gold standard diagnostic method. Evidence suggests that polymerase chain reaction (RT–PCR) for Coronavirus nucleic acid has a low sensitivity and computed tomography (CT) has been suggested for more accurate diagnosis. Yet, CT has the disadvantage of radiation and is not safe in all patients. Here, we present a case series of 23 patients who underwent both RT–PCR and CT and report the outcome.
https://jkmu.kmu.ac.ir/article_91615_b4f3b39de30d6208de7516d3253fed93.pdf
2021-03-01
187
193
10.22062/jkmu.2021.91615
COVID
19 Coronavirus Tomography Spiral Computed Real
Time Polymerase Chain Reaction
Bahram
Moazzami
bahrammoazzami@gmail.com
1
Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Moezedin Javad
Rafiee
javadrafiee2003@yahoo.com
2
Depts of Medicine and Diagnostic Radiology, McGill University Health Center -Research Institute, Canada
LEAD_AUTHOR
Saeed
Samie
ssamie@parsgeneralhospital.com
3
Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Ramin
Lak
lak_ramin@yahoo.com
4
Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Faranak
Babaki Fard
faranakbabaki@yahoo.com
5
Babak Imaging Center, Pars Hospital, Tehran, Iran
AUTHOR
Kaveh
Samimi
kavehsamimi@gmail.com
6
Babak Imaging Center, Pars Hospital, Tehran, Iran
AUTHOR
Pardis
Rafiee
par_rafiee@yahoo.com
7
Babak Imaging Center, Pars Hospital, Tehran, Iran
AUTHOR
Shadi
Erfanian Asl
sh.physician@gmail.com
8
Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Meisam
Akhlaghdoust
meisam_akhlagh@yahoo.com
9
Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Shahla
Chaichian
shchaichian@gmail.com
10
Professor, Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4):281-6.
1
Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol 2020; 127:104371.
2
Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. The Lancet Global Health 2020; 8(4):1-9.
3
WHO. Coronavirus disease 2019 (COVID-19). [cited 2020 May 22] Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f8_4.
4
Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology 2020; 296(2):E15-25.
5
Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020; 94:154-5.
6
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3):2000045.
7
Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 2004; 15(3):155-66.
8
Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn 2020; 20(5):453-4.
9
Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 2020; 296(2):E115-7.
10
Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology 2020; 295(1):22-3.
11
Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020; 296(2):E41-5.
12
Kalra MK, Maher MM, Rizzo S, Kanarek D, Shephard JA. Radiation exposure from chest CT: issues and strategies. J Korean Med Sci 2004; 19(2):159-66.
13
European Society of Cardiology (ESC). ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. [cited 2020 June 29] Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.
14
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies. Eur Radiol 2020; 30(9):4930-42.
15
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323(14):1406-7.
16
Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020 ;63(5):706-11.
17
Tang YW, Schmitz JE, Persing DH, Stratton CW. The laboratory diagnosis of COVID-19 infection: current issues and challenges. J Clin Microbiol 2020; 58(6):e00512-20.
18
Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon A, et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19. J Clin Microbiol 2020; 58(5):e00297-20.
19
Radpour A, Bahrami-Motlagh H, Taaghi MT, Sedaghat A, Karimi MA, Hekmatnia A, et al. COVID-19 evaluation by low-dose high resolution CT scans protocol. Acad Radiol 2020; 27(6):901.
20
Feng H, Liu Y, Lv M, Zhong J. A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT. Jpn J Radiol 2020; 38(5):409-10.
21
Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020; 295(3):685-91.
22
Committee GOoNH. Office of state administration of traditional Chinese medicine. Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial version 6)[text in Chinese. 2020.
23
Yang W, Yan F. Patients with RT-PCR-confirmed COVID-19 and normal chest CT. Radiology 2020; 295(2):E3.
24
Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA 2020; 323(15):1502-3.
25
Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020; 296(2):E32-40.
26
Costello JE, Cecava ND, Tucker JE, Bau JL. CT radiation dose: current controversies and dose reduction strategies. AJR Am J Roentgenol 2013; 201(6):1283-90.
27
Forrester JD, Nassar AK, Maggio PM, Hawn MT. Precautions for operating room team members during the COVID-19 pandemic. J Am Coll Surg 2020; 230(6):1098-101.
28
West CP, Montori VM, Sampathkumar P. COVID-19 testing: the threat of false-negative results. Mayo Clin Proc 2020; 95(6):1127-9.
29
ORIGINAL_ARTICLE
Concomitant Dislocation of Proximal and Distal Interphalangeal Joints of Small Finger: A Case Report
A 24 old man sustained an injury to his right hand when playing soccer as goalkeeper, most probably from a direct strike for the ball or offender foot. On physical examination the injury was limited to the right middle finger, which was swollen, tender an essentially no active motion could be observed in none of the interphalangeal joints. The injury was a close one and no wound or nerve injury was present. No evidence of compartment syndrome was observed. The neurovascular examination was normal. Radiograms were taken immediately which revealed double dislocation of both interphalangeal joints in the right fifth finger. Closed reduction under general anaesthesia was performed and early active and passive range of motion was began as soon as possible. In follow up full range of motion of the joints was retained. The case emphasizes the necessity of whole finger radiologic examination in distal interphalangeal dislocations in the hand.
https://jkmu.kmu.ac.ir/article_91616_ad91363a7ec00969e1909d3ce2dc3691.pdf
2021-03-01
194
198
10.22062/jkmu.2021.91616
Hand
dislocation
Finger
Alireza
Saied
arsaiedmd@yahoo.com
1
Kerman University of Medical SciencesAssociate Professor, Kerman University of Medical Sciences
LEAD_AUTHOR
Bartels M. Traumatische Luxationen. Arch Chir 1874; 16:636-54.
1
Seki Y. Simultaneous double dislocation of the interphalangeal joint of the same finger: a report of two cases. Pan Afr Med J 2014; 19:400.
2
Van Ransbeeck H, De Smet L. Double dislocation of both interphalangeal joints in the finger. Case report and literature review. Acta Orthop Belg 2004; 70(1):72-5.
3
Abdelaal A, Edwards T, Anand S. Simultaneous dislocation of both the proximal and distal interphalangeal joints of a little finger. BMJ Case Rep 2016; 2016:bcr2015213914.
4
Hara K, Uchiyama S, Kato H. Irreducible simultaneous dislocation of both interphalangeal joints in the little finger: a case report. Hand Surg 2009; 14(1):39-42.
5
Kim YS, Song HS, Kim HM, Chung E, Park IJ. Simultaneous double dislocation of the interphalangeal joint in a finger. Arch Orthop Trauma Surg 2009; 129(10):1387-90.
6
Jahangiri SA, Mestha P, McNally S. Double dislocation of finger interphalangeal joints. BMJ Case Rep 2012; 2012.
7
Andersen MB, Johannsen H. Double dislocation of the interphalangeal joints in the finger. Case report and review of publications. Scand J Plast Reconstr Surg Hand Surg 1993; 27(3):233-6.
8
ORIGINAL_ARTICLE
Hiccups, a Rare Presentation of Infective Endocarditis: A Case Report
Hiccup has a wide variety of etiologies irritating the hiccup reflex arc. It is usually benign and self-limited but can be an alarm sign for serious underlying conditions. Hiccup has been rarely reported in patients with infective endocarditis as a result of splenic involvement and phrenic nerve irritation. Herein, we report a 72-year-old man with the chief complaint of long-lasting hiccups (for a 1-month duration) who was diagnosed with infective endocarditis; however, his spleen was grossly intact. The bouts of hiccups repeated 2-3 times a day and lasted for 10-20 minutes. After the initiation of antibiotics, his symptoms waned for a while and appeared again, and then, the hiccups were eliminated. Long-lasting hiccups can be a presentation of serious medical conditions such as infective endocarditis, with or without splenic involvement. Hence, it is important to keep in mind these conditions to perform proper diagnostic and therapeutic workups.
https://jkmu.kmu.ac.ir/article_91617_a5529a1940c636e9bae519b4e86b95d3.pdf
2021-03-01
199
203
10.22062/jkmu.2021.91617
Infective Endocarditis
Fever of Unknown Origin
Intractable Hiccups
Hale
Afshar
afshar.hale@gmail.com
1
Assistant Professor of Pulmonary Diseases, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Sina
Bakhshaei
sina.bakhshaei@gmail.com
2
General practitioner, Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Masoumeh
Kahnooji
kahnooji4868@gmail.com
3
Assistant Professor of Cardiology, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mohsen
Shafiepour
m.shafiepour@kmu.ac.ir
4
Assistant Professor of Pulmonary Diseases, Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran; Department of Internal Medicine, School of Medicine, Kerman University of Medical Sciences, Kerman
LEAD_AUTHOR
Ahmad
Alinaghi Langari
a.alinaghi.langari@gmail.com
5
General practitioner, Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Krakauer EL, Zhu AX, Bounds BC, Sahani D, McDonald KR, Brachtel EF. Case 6-2005: a 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups. New England Journal of Medicine 2005; 352(8):817-25.
1
Wilcox SK, Garry A, Johnson MJ. Novel use of amantadine: to treat hiccups. J Pain Symptom Manage 2009; 38(3):460-5.
2
Launois S, Bizec JL, Whitelaw WA, Cabane J, Derenne JP. Hiccup in adults: an overview. Eur Respir J 1993; 6(4):563-75.
3
Chang FY, Lu CL. Hiccup: mystery, nature and treatment. J Neurogastroenterol Motil 2012; 18(2):123-30.
4
Hosny SM, Rasheedy D. A Case of Intractable Hiccup Ended Badly. Egyptian Journal of Geriatrics and Gerontology 2014; 1(2):19-25.
5
Kalaycı B, Karabag T, Erten T, Akgun T. Pacemaker lead endocarditis with hiccups (Kalayci). Caspian J Intern Med 2018; 9(3):299-302.
6
Wiener C, Kasper DL, Fauci A, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine Self-Assessment and Board Review. 19th ed. USA: McGraw-Hill Education; 2016. p. 135-8.
7
Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. Am J Med 2015; 128(10):1138.
8
Celik T, Kose S, Bugan B, Iyisoy A, Akgun V, Cingoz F. Hiccup as a result of late lead perforation: report of two cases and review of the literature. Europace 2009; 11(7):963-5.
9
Krysiak W, Szabowski S, Stepien M, Krzywkowska K, Krzywkowski A, Marciniak P. Hiccups as a myocardial ischemia symptom. Pol Arch Med Wewn 2008; 118(3):148-51.
10
Davenport J, Duong M, Lanoix R. Hiccups as the only symptom of non-ST-segment elevation myocardial infarction. Am J Emerg Med 2012; 30(1):266.
11
ORIGINAL_ARTICLE
Estimation of the Normal Upper Limits for Serum Alanine Aminotransferase in a Population-Based Study from Southeast of Iran
Background: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are two accessible indices for liver evaluation. Upper limit of normal (ULN) of these tests are important for starting further investigations for persons with high values. In recent years, cut off points for ULN of these tests have been disputed. This study aimed to determine the ULN of ALT and AST in a population-based study. Methods: This cross-sectional study was performed on a randomized clustered sample of people of Kerman city. Demographic, anthropometric, and laboratory data were collected and analyzed. After excluding the recognized risk factors for liver function tests in another group (group 2), data were analyzed in this subgroup. Results:Of 2748 subjects included in this study, 1172 (42.4%) were men, with an age range of 15-85 years. The mean (± SE), median, mode, and 95th percentile were 23.74 ± 0.18, 22, 19, and 37 for AST and 22.37 ± 0.27, 18, 15, and 46 for ALT, respectively. The levels of AST and ALT were higher in men and middle age group (p <0.0001). Similar results were obtained for gender but the association of AST and ALT with age was disappeared in another group. Conclusion: According to the results of the present study, it is recommended to measure the ULN of AST and ALT periodically in different regions concerning age and gender.
https://jkmu.kmu.ac.ir/article_91618_73485258a0f56d00e893f3ce582b4952.pdf
2021-03-01
204
211
10.22062/jkmu.2021.91618
Alanine Aminotransferase
Aspartate Aminotransferase
General Population
Upper Limit of Normal
Sodaif
Darvish Moghadam
sdmoghadam@kmu.ac.ir
1
Professor of Gastroenterology and Hepatology, Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mohammad Javad
Zahedi
zahedimj@yahoo.com
2
Professor of Gastroenterology and Hepatology, Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mohammad Mahdi
Hayatbakhsh Abbasi
3
Professor of Internal Medicine, Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Ali Akbar
Haghdoost
4
Professor of Epidemiology, Research Center for Modeling in Health, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mahdieh
Khalily Zade
mkhalili@kmu.ac.ir
5
Infectious Disease Specialist, Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Mehdi
Khaleghinia
khnia.info@gmail.com
6
Infectious Disease Specialist, Samen Hepatitis Clinic, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Azam
Dehghani
a.dehghani63@yahoo.com
7
MSc of Biostatistics, Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Sara
Shafieipour
sarashafieipour@yahoo.com
8
Assistant Professor of Gastroenterology and Hepatology, Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998;27(5):1213-9.
1
Kariv R, Leshno M, Beth-Or A, Strul H, Blendis L, Kokia E, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006;26(4):445-50.
2
Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010;51(5):1577-83.
3
Volzke H, Alte D, Ittermann T, Schmidt CO, Rettig R, Mayerle J, et al. Subjects with sonographical hepatic steatosis should be excluded from studies to establish upper reference levels of serum transaminases. Liver Int 2011;31(7):985-93.
4
Zheng MH, Shi KQ, Fan YC, Liu WY, Lin XF, Li LF, et al. Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PloS one 2012; 7(9):e43736.
5
Wu WC, Wu CY, Wang YJ, Hung HH, Yang HI, Kao WY, et al. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects. Aliment Pharmacol Ther. 2012;36(6):560-8.
6
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137(1):1-10.
7
Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism 2012; 61(8):1182-8.
8
Elinav E, Ben-Dov IZ, Ackerman E, Kiderman A, Glikberg F, Shapira Y, et al. Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol. 2005; 100(10):2201-4.
9
Grossi E, Colombo R, Cavuto S, Franzini C. Age and gender relationships of serum alanine aminotransferase values in healthy subjects. The Am J Gastroenterol 2006; 101(7):1675-6.
10
Kang HS, Um SH, Seo YS, An H, Lee KG, Hyun JJ, et al. Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population. J Gastroenterol Hepatol 2011; 26(2):292-9.
11
Kabir A, Pourshams A, Khoshnia M, Malekzadeh F. Normal limit for serum alanine aminotransferase level and distribution of metabolic factors in old population of kalaleh, iran. Hepat Mon 2013; 13(10):e10640.
12
Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, et al. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PloS one 2011; 6(6):e21178.
13
Sull JW, Yun JE, Lee S-Y, Ohrr H, Jee SH, Guallar E, et al. Body mass index and serum aminotransferase levels in Korean men and women. J cli gastroenterol 2009;43(9):869-75.
14
Al-hamoudi W, Ali S, Hegab B, Elsiesy H, Hashim A, Al-Sofayan M, et al. Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology. Dig Dis Sci 2013; 58(8):2369-75.
15
Dong MH, Bettencourt R, Barrett-Connor E, Loomba R. Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PloS one 2010; 5(12):e14254.
16
Jamali R, Pourshams A, Amini S, Deyhim M-R, Rezvan H, Malekzadeh R. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med 2008; 11(6):602-7.
17
Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55(2):447-54.
18
Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, et al. Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatol Res 2014: 44(12):1196-207.
19
Pacifico L, Ferraro F, Bonci E, Anania C, Romaggioli S, Chiesa C. Upper limit of normal for alanine aminotransferase: Quo vadis? Cli Chim Acta 2013; 422:29-39.
20
ORIGINAL_ARTICLE
Genetic Association of ADIPOQ Gene Variant (rs822396) with Type 2 Diabetes in Iranian Patients
Background: Genetic and environmental factors influence serum adiponectin and may contribute to the risk of metabolic syndrome and type 2 diabetes (T2D). There are many studies conducted to investigate the association between different polymorphisms of the ADIPOQ geneand T2D risk in all around the world. Therefore, the present study was conducted to investigate the association between adiponectin gene (ADIPOQ) polymorphism (rs822396) and the risk of T2D, which has not been studied yet in the Iranian patients. Methods: Selected SNP was genotyped in 40 T2D patients and 40 controls by PCR amplification and direct Sanger sequencing. Fisher's exact test and Chi2 test were used to estimate the risk of T2D associated with the selected SNP, and genotypic and allelic distributions were compared between the case and control groups. Results: It was revealed that there were no significant differences in the distribution of genotypes and allele frequencies of rs822396 between Iranian patients with T2D and controls. Conclusion: According to the results, -3971 A/G polymorphism is unlikely to be involved in the susceptibility to or the severity of T2D in Iranian patients. Further large prospective studies are required to confirm these findings.
https://jkmu.kmu.ac.ir/article_91619_4231d750d282eaf649b3ed5a440b6024.pdf
2021-03-01
212
218
10.22062/jkmu.2021.91619
Diabetes
ADIPOQ
Polymorphism
Iranian
Behnaz
Hezarkhani
1000khani.bhnaz@gmail.com
1
Departments of Molecular and Cellular Biology, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran
AUTHOR
Seyedeh Parisa
Chavoshi Tarzjani
romisa_magic@yahoo.com
2
Department of Genetic, Faculty of Biological Science, Tehran North Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Zahra
Sadeghi
3
Department of Genetic, Faculty of Biological Science, Tehran North Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Seyedeh Mohadese
Shahzadeh Fazeli
mshfazeli@yahoo.com
4
Department of Medical, Alborz Medical University, Karaj, Iran
AUTHOR
Zahra
Mirzayee
fazeli.sanati.geneticlab@gmail.com
5
Fazeli-Sanati Genetics Laboratory, Tehran, Iran
AUTHOR
Seyed Abolhassan
Shahzadeh Fazeli
shfazeli@yahoo.com
6
Professor, Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
LEAD_AUTHOR
Zhao N, Li N, Zhang S, Ma Q, Ma C, Yang X, et al. Associations between two common single nucleotide polymorphisms (rs2241766 and rs1501299) of ADIPOQ gene and coronary artery disease in type 2 diabetic patients: a systematic review and meta-analysis. Oncotarget 2017; 8(31):51994-2005.
1
Chaikhiandee S, Phonrat B, Tungtrongchitr A, Suriyaprom K, Chuengsamarn S, Uttamachai C, et al. Adipoq polymorphisms among thais with pre-diabetes. Southeast Asian J Trop Med Public Health 2016; 47(6):1306-14.
2
Chu H, Wang M, Zhong D, Shi D, Ma L, Tong N, et al. AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a meta‐analysis study. Diabetes Metab Res Rev2013; 29(7):532-45.
3
Zhang H, Pollin TI. Epigenetics variation and pathogenesis in diabetes. Curr Diab Rep 2018; 18(11):121.
4
Misra A, Sattar N, Tandon N, Shrivastava U, Vikram NK, Khunti K, et al. Clinical management of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol 2018; 6(12):979-91.
5
Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al. The genetic architecture of type 2 diabetes. Nature 2016; 536(7614):41-7.
6
Kyriakou T, Collins LJ, Spencer-Jones NJ, Malcolm C, Wang X, Snieder H, et al. Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity. J Hum Genet 2008; 53(8):718-27.
7
Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11(8):327-32.
8
Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004; 53(9):2473-8.
9
Marseglia L, Manti S, D'Angelo G, Nicotera A, Parisi E, Di Rosa G, et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 2014; 16(1):378-400.
10
Kitamoto A, Kitamoto T, So R, Matsuo T, Nakata Y, Hyogo H, et al. ADIPOQ polymorphisms are associated with insulin resistance in Japanese women. Endocr J 2015; 62(6):513-21.
11
Ramya K, Ayyappa KA, Ghosh S, Mohan V, Radha V. Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population. Gene 2013; 532(2):253-62.
12
Warodomwichit D, Shen J, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, et al. ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study. Obesity (Silver Spring) 2009; 17(3):510-7.
13
Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3(1):35-42.
14
Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50(5):1126-33.
15
Jee SH, Sull JW, Lee JE, Shin C, Park J, Kimm H, et al. Adiponectin concentrations: a genome-wide association study. Am J Hum Genet 2010; 87(4):545-52.
16
Dendana M, Bahia W, Finan RR, Al-Mutawa M, Almawi WY. Association of adiponectin gene variants with idiopathic recurrent miscarriage according to obesity status: a case-control study. J Transl Med 2018; 16(1):76.
17
Biswas D, Vettriselvi V, Choudhury J, Jothimalar R. Adiponectin gene polymorphism and its association with type 2 diabetes mellitus. Indian J Clin Biochem 2011; 26(2):172-7.
18
Kang ES, Magkos F, Kim BS, Zhai R, Su L, Kim YS, et al. Variants of the adiponectin and adiponectin receptor-1 genes and posttransplantation diabetes mellitus in renal allograft recipients. J Clin Endocrinol Metab 2012; 97(1):E129-35.
19
Mtiraoui N, Ezzidi I, Turki A, Chaieb A, Mahjoub T, Almawi WY. Single-nucleotide polymorphisms and haplotypes in the adiponectin gene contribute to the genetic risk for type 2 diabetes in Tunisian Arabs. Diabetes Res Clin Pract 2012; 97(2):290-7.
20
Tso AW, Sham PC, Wat NM, Xu A, Cheung BM, Rong R, et al. Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia 2006; 49(8):1806-15.
21
Wassel CL, Pankow JS, Jacobs DR Jr, Steffes MW, Li N, Schreiner PJ. Variants in the adiponectin gene and serum adiponectin: the Coronary Artery Development in Young Adults (CARDIA) Study. Obesity (Silver Spring) 2010; 18(12):2333-8.
22
Mofarrah M, Ziaee S, Pilehvar-Soltanahmadi Y, Zarghami F, Boroumand M, Zarghami N. Association of KALRN, ADIPOQ, and FTO gene polymorphism in type 2 diabetic patients with coronary artery disease: possible predisposing markers. Coron Artery Dis 2016; 27(6):490-6.
23
Erfanian S, Moradzadeh M, Solhjoo K, Jahromi AS. Data describing the association between rs266729 polymorphism inadiponectin promoter gene and Type 2 Diabetes Mellitus. Data Brief 2016; 9:1138-40.
24
Namvaran F, Rahimi-Moghaddam P, Azarpira N, Dabbaghmanesh MH. Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. Mol Biol Rep 2012; 39(5):5511-8.
25